5 of Last Week's Biggest Losers

There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.

Source: Barron's.

Let's start with Amarin. The former high-flying biotech continues its dramatic fade in 2013. The stock has shed nearly 80% of its value this year, and it's now trading at its lowest level in more than three years. This week's 25% blow came after the Food and Drug Administration announced that its triglyceride-reducing drug Vascepa may not merit approval in lowering the cardiovascular problems in select patients. It also didn't help that FBR Capital initiated coverage on Amarin with a ho-hum "market perform" rating and a price target that was below where it was trading at the time. Amarin did close out the week below FBR's $2 price target.

Hutchinson's drop came largely on Friday, after it posted an adjusted loss of $0.40 a share on flat revenue growth. Analysts were expecting only $0.24 a share in red ink, making this the second consecutive quarter where Hutchinson delivers a much larger deficit than Wall Street was forecasting. The future won't get a whole lot better. Hutchinson sees suspension assemblies for the new quarter clocking in essentially flat sequentially.

Ellie Mae investors were in dismay after the mortgage-processing solutions provider posted disappointing financial results. Ellie Mae was smacked down by a drop in mortgage origination volume. It tried to overcome the sloppy results with the acquisition of MortgageCEO -- a provider of CRM and marketing solutions -- but investors still chose to cash out given the decaying fundamentals of the mortgage industry in general.

Eagle Rock Energy Partners became the latest master limited partnership to slash its yield, announcing that it would pay just $0.15 per unit this quarter. It has previously shelled out $0.22 per unit. Given the partnership's leveraged balance sheet and its soft earnings that made the higher payout rate unsustainable, some market watchers saw this coming, but too many investors were spoiled by high yield without considering the likely reduction.

Teva slipped after its CEO was let go. The Israeli-based drug company also served up uninspiring quarterly results. Revenue inched 2% higher, but earnings moved in the other direction. It also didn't help that the CEO's departure wasn't entirely clear. Teva's official announcement was that he stepped down, but he told a reporter it wasn't his decision to resign. It can't help that Teva is expanding its bribery investigation into Eastern Europe, casting even more clouds over the pharmaceuticals giant.